FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileDrugs Made In America Acquisition II Corp. Unit
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DMIIU
Drugs Made In America Acquisition II Corp. Unit Stock AnalysisComprehensive stock analysis for Drugs Made In America Acquisition II Corp. Unit (DMIIU) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisDMIIU
DMIIU
Drugs Made In America Acquisition II Corp. Unit
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
DMIIU
  1. Home
  2. Stocks
  3. Drugs Made In America Acquisition II Corp. Unit

Drugs Made In America Acquisition II Corp. Unit

🇺🇸DMIIU•NASDAQ

Drugs Made In America Acquisition II Corp. Unit

🇺🇸DMIIU•NASDAQ
Market cap
$651.65M
Sentiment

Your view on DMIIU

Mkt Cap
$651.65M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Drugs Made In America Acquisition II Corp. Unit

Industry
Shell Companies
Sector
Financial Services
CEO
Roger Bendelac
Headquarters
420 Lexington Avenue, New York, NY, US
Industry
Shell Companies
Sector
Financial Services
CEO
Roger Bendelac
Headquarters
420 Lexington Avenue, New York, NY, US
Description

DMIIU is a Special Purpose Acquisition Company (SPAC), operating as a blank check firm established in the Cayman Islands. Its core objective is to identify and complete a merger or acquisition with an existing business.

The company specifically aims to acquire targets within the pharmaceutical and drug industries, driven by the goal of reducing the United States' reliance on international drug manufacturing.

Each investment unit comprises one common stock share and an associated right, which entitles the holder to an additional one-tenth of a share once a suitable business combination is successfully finalized.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Drugs Made In America Acquisition II Corp. Unit from FRC's valuation model, read against the market price. DMIIU last traded at $10.25, 33.8× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Drugs Made In America Acquisition II Corp. Unit. Starting points for Drugs Made In America Acquisition II Corp. Unit: P/E 33.8, EPS $0.26, beta 0.06 — an Shell Companies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Drugs Made In America Acquisition II Corp. Unit. Drugs Made In America Acquisition II Corp. Unit does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Drugs Made In America Acquisition II Corp. Unit. Trailing twelve-month EPS for Drugs Made In America Acquisition II Corp. Unit stands at $0.26. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Drugs Made In America Acquisition II Corp. Unit. Drugs Made In America Acquisition II Corp. Unit has reported as a listed company since 2025. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold DMIIU12 companies

More Shell Companies companies

Market cap

  • GIXXUGigCapital9 Corp. UnitsNASDAQ$261M
  • GLBBGlobal Quest Ltd.OTC$1,005
  • GLEDGalaxyEdge Acquisition CorporationNYSE$163M
  • GLRIGlori Energy Inc.OTC$6,474
  • GMZPGEMZ CorporationOTC$222,599
  • GPACGeneral Purpose Acquisition Corp.NASDAQ$240M
  • GPACUGeneral Purpose Acquisition Corp.NASDAQ$241M
  • GPATGP-Act III Acquisition Corp.NASDAQ$176M
  • GPATUGP-Act III Acquisition Corp.NASDAQ$392M
  • GPATWGP-Act III Acquisition Corp.NASDAQ$275M
  • GPLBGreen Planet Bioengineering Co LtdOTC$342,109
  • GRGGGreen For Energy, Inc.OTC
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Drugs Made In America Acquisition II Corp. Unit executives and directors. Shares of Drugs Made In America Acquisition II Corp. Unit have traded between $9.94 and $10.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Drugs Made In America Acquisition II Corp. Unit. Coverage tracks Drugs Made In America Acquisition II Corp. Unit within Shell Companies (Financial Services). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Drugs Made In America Acquisition II Corp. Unit.

DMIIU Analysis
Weak
Past2
Growth1
Health1
Profit1
Value1

News

Latest Market News